Related Experiment Video
Updated: Aug 6, 2025
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Radiofrequency ablation for renal tumours: A retrospective study from a tertiary centre
Mohammed Al-Zubaidi1, Kennia Lotter1, Martin Marshall2
1Department of Urology, Royal Perth Hospital, Perth, Australia.
Objective:
This study aimed to evaluate the safety and efficacy outcomes of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) in a tertiary hospital patient who remained unfit for surgical intervention.
Methods:
We retrospectively analysed survival outcomes for patients with biopsy proven RCC treated by RFA at Royal Perth Hospital between September 2009 and May 2018. Complication data were gathered for all patients that underwent renal RFA along with 2- and 5-year recurrence-free survival (RFS) rate and compared the outcomes with data from previous studies.
Results:
A total of 69 patients (73 procedures) were eligible for the study, and those patients had biopsy-proven RCC with a minimum of 2-year follow-up. The complication rate was 8.2% (6/73) and local recurrence rate 9.6% (7/73). Two-year RFS is 95.7% and 5-year RFS is 78.8% on a median 3.82-year follow-up (interquartile range 1.90-5.75 years).
Conclusion:
RFA performed at our centre was found to be safe and effective with low complication rates and durable RFS in line with expectations from existing research. Our study demonstrated that RFA is an alternative modality of treatment for small renal tumours in patients unfit for surgical approach.
